Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting

Reuters

2025/05/23

Abbisko <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting

Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537975125"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537975125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537975125?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537975125","market":"us","top_or_hot":-1,"title":"Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-23 08:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL2bqVBy:1","article_id":"2537975125","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537975125","pubTimestamp":1747958664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology  Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor . The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","02256":"和誉-B"},"translate_title":"Abbisko Therapeutics将在2025年ASCO年会上展示匹米替尼3期研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":0.9},"content_text":"Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    \n\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}